For Medical Professionals

Information for Medical Professionals

Personalised Breast Cancer Prevention is an up-to-date solution aimed at minimizing the potential impact of breast cancer by tailoring it to a woman’s genetic risk level.

It begins with polygenic risk score testing (AnteBC test), as polygenic risk score is the strongest independent risk factor for breast cancer. Based on the test results, women receive personalised medical plans for screening and prevention.

This guidance includes when and how to initiate breast cancer screening and other effective strategies (hormonal medical prevention, health behaviour changes) to reduce personal risks. The service also includes a family history questionnaire for breast cancer, based on which it is determined whether the woman requires additional testing for rare monogenic pathogenic variants (in genes such as BRCA1, BRCA2, etc.).

Armed with scientifically backed and well-documented medical advice, women can take preventive measures within their local healthcare system to protect their health proactively.

Recommended for women aged 30-75.

The service includes:

Polygenic risk assessment of breast cancer (AnteBC test) combined with age, population background and ethnic information.
Medical plans with clinical recommendations based on personal polygenic risk level for breast cancer prevention and early detection.
Family cancer history questionnaire to assess the need for monogenic pathogenic variant (MPV) testing; if indicated, recommendations for a medical geneticist consultation and MPV testing. Based on family history criteria for breast cancer, women can also undergo MPV testing through their GP within the NHS system. The current service determines the need for this.
Following possibilities to implement breast cancer prevention and control according to personalised medical plans (relevant information is provided in these personalised medical plans).
Optional: possibilities for additional verbal counselling and consultations with medical professionals.
As next steps, it is possible for women in breast clinics and through GPs to complement their genetic risk assessment with additional information based on mammographic breast density following mammography, as well as using combined risk assessment models (such as the CanRisk and Tyrer-Cuzick models). Based on family history criteria for breast cancer, women may undergo MPV testing through their GP within the NHS system.
Optional: if a combined breast cancer risk assessment model (as the CanRisk or Tyrer-Cuzick model) is used in clinical practice, the AnteBC test result can be integrated into the model to provide the more accurate and regulatory compliant information for clinical practice.

Additional information:

Members of the Personalised Breast Cancer Prevention Consortium are among the leading experts who have developed and published international clinical guidelines for the clinical use of the breast cancer polygenic risk scores in personalised breast cancer prevention:

Read the scientific background